The orthopedics market is poised for significant growth, driven by technological advancements, an aging global population, and a rising incidence of musculoskeletal disorders.

In 2024, the global orthopedic market is expected to surpass $59 billion, reflecting a robust growth rate of 6.5% compared to the previous year, which exceeds the industry’s historical average by three percentage points.

Key Players in the Orthopedics Market

Major players currently dominating the orthopedic market include DePuy Synthes, Medtronic, Smith+Nephew, Stryker, and Zimmer Biomet. 

These companies are continually innovating and expanding their product portfolios. For instance, in recent developments:

• DePuy Synthes launched its TriALTIS pedicle screw system.
• Medtronic has been recognised for its ethical standards and continues to be a leader in spine and orthopedic products.
• Smith+Nephew made its Aetos Shoulder System fully commercially available in the U.S.
• Stryker surpassed $20 billion in full-year sales for the first time in 2023.
• Zimmer Biomet continues to innovate in orthopedic implants and digital technologies.

Investment Trends

The investment landscape in orthopedics has shifted towards later-stage companies with clear paths to profitability. Despite a slow pace of investment in 2023, the average investment amount has nearly doubled the historical average, totaling approximately $637 million across 27 investments.

Technological Advancements in Orthopedics

The orthopedics sector is at the forefront of technological integration, with significant developments in robotics, artificial intelligence (AI), and personalised medicine reshaping surgical procedures and patient care. 

Robotics technology, for instance, is being increasingly adopted for knee and hip surgeries to enhance precision and reduce recovery times. This trend is supported by the development of devices like the MAKO robotic-arm assisted technology by Stryker, which allows for more accurate implant positioning compared to traditional techniques​.

Moreover, AI is transforming patient management through predictive analytics and personalised treatment plans. AI applications range from diagnostic algorithms that enhance imaging interpretation to machine learning models that predict patient outcomes and optimize treatment protocols​​. 

Additionally, advancements in 3D printing are facilitating the production of custom implants tailored to the individual anatomical requirements of patients, which improves compatibility and comfort​​.

Geographic Trends

The global orthopedics market exhibits diverse geographic trends, with significant growth opportunities in both developed and emerging markets. 

In developed regions such as North America and Europe, the market is driven by an aging population, high healthcare expenditure, and the widespread adoption of advanced orthopedic solutions​. 

Conversely, the Asia-Pacific region is witnessing rapid market expansion due to increasing economic affluence, greater healthcare access, and rising awareness about orthopedic conditions.

China and India are particularly notable due to their large geriatric populations and growing healthcare infrastructure, which are expected to fuel demand for orthopedic procedures. 

Additionally, the rise in medical tourism in countries like Thailand and Malaysia, known for cost-effective medical care, is attracting patients globally, further stimulating the regional markets​.

Future Outlook

The orthopedics market is set for sustained growth, driven by continuous innovation and an increasing burden of orthopedic conditions globally. Future market dynamics are likely to be influenced by ongoing technological advancements, demographic shifts, and evolving patient expectations. 

The market is also expected to benefit from a higher incidence of lifestyle diseases such as obesity and diabetes, which contribute to joint and bone issues, thereby increasing the demand for orthopedic care​.

In the coming years, the integration of biologics with traditional orthopedic treatments could offer new growth avenues, particularly in regenerative medicine. Biologics are gaining traction for their potential to enhance healing and recovery in bone and soft tissue repairs. 

The orthopedic industry is also likely to see a shift towards more outpatient and minimally invasive surgeries, which could decrease hospital stays and healthcare costs, further driven by patient preference for less invasive treatment options​​.

As the industry navigates through these changes, strategic mergers and acquisitions are expected to continue, enabling companies to broaden their technological capabilities and geographic reach. 

This environment creates a fertile ground for innovations and collaborations that could significantly improve patient outcomes and efficiency within the healthcare system​.

Integration with Data Orchestration: Vamstar’s Role

In such a dynamically growing industry, efficient data management becomes crucial. Vamstar’s data orchestration capabilities could play a pivotal role by enhancing data integration from various sources. 

This includes ERPs, wholesalers, and inventory systems, which is vital for managing spend, supplier relationships, and contract sourcing. 

The comprehensive approach ensures data quality and utility, supporting advanced analytics essential for making informed decisions in the fast-evolving orthopedics market.

The continued innovation and robust investment in the orthopedics sector signify a vibrant future, potentially revolutionised further by advanced data management and analysis technologies like those offered by Vamstar.

Editorial Note:

This article features a more recent rewrite.

Profits are steadily eroding in the pharmaceutical industry – thanks to rising costs across labour and raw materials, alongside persistent price pressure. Getting drug pricing right is therefore more important than ever.

Traditional methods to set and negotiate drug pricing over the lifetime of a drug fail to leverage the wealth of available data and therefore limit profitability. It also poses the risk of costly mistakes: just consider the embarrassing climb-down by Aduhelm maker Biogen, for example.

Vamstar addresses these challenges by harnessing AI combined with a meticulously curated dataset to streamline and automate the pricing and negotiation process.

From assembling and refining relevant data to applying sophisticated pattern recognition and predictive analytics, read on to see how Vamstar’s Polaris platform helps suppliers set optimal prices in a tough market.

Manually setting prices is inherently risky

In life sciences, optimal pricing maximises value, minimises risk, and ultimately improves patient outcomes. Nonetheless, suppliers often rely on outdated, error-prone methods to set their prices – errors that can be very costly across multi-year contracts. The source of the problem looks roughly like this:

• The Excel trap: Excel was never suited to the complexities of pharmaceutical pricing. Modelling dynamic market factors, competitor strategies, and intricate cost structures using a spreadsheet is cumbersome and risk prone. Formulas get misaligned, data becomes outdated, and costly errors inevitably creep in.
• Oversimplified models: Simple cost-plus pricing functions as a baseline, but it fails to offer any modelling depth in a market that is nuanced and complex. Simplified models won’t reflect the true potential of a product in comparison to the competition, nor the willingness (and ability) of payers to improve their offers.
• Revenue management falls short: Past attempts using revenue-management platforms did improve pricing management, but revenue management platforms are not built with the specific goal of price optimisation in mind and cannot model drug prices.
• Untapped data goldmine: A treasure trove of valuable pricing data is going unutilised. Market share information, historical pricing trends, and competitor intelligence are all available in public data sets, but these data sets are scattered and disconnected. Current pricing methods offer no way to integrate and make sense of this vast pool of insights.

The net result is missed profit opportunities, vulnerability to competitor moves, and less-than-ideal value delivered to payers and to patients, risking suboptimal patient care.

Complex negotiations require extensive analytics

Setting prices for pharmaceuticals is far from a one-and-done task. It’s an intricate dance involving internal calculations, external market dynamics, and ultimately, a value proposition that convinces payers.

Comprehensive and up-to-date data, deep and broad analytics, and a good measure of automation lead to a more accurate and more defensible process of setting initial prices. It means that suppliers can include market trends, comparable products, and the unique benefits a drug offers in their pricing decisions.

Furthermore, these insights help manufacturers optimise pricing through the lifecycle of the drug – providing much-needed data during complex negotiations.

Payers will naturally seek to minimise costs, often armed with internal datasets. Here, concrete pricing data provides the firepower to counter objections and negotiate from a position of strength.

Detailed market analysis, insights into competitor pricing, and even historical trends on discounts – all provide leverage. Extensive analytics and data also offer supporting evidence in a world of evolving regulations and heightened scrutiny around drug costs.

Data, AI, and automation from Vamstar

To secure the value of innovation, drug manufacturers must find a way to collect and analyse the data that support pricing decisions – but that’s easier said than done. At Vamstar, we developed a pricing product that utilises a deep pool of data, carefully applied AI, and purpose-built automation to deliver unprecedented control over the pricing process. It works like this:

Step 1: Assembling and refining a Pharma dataset

The first obstacle to setting pricing is the fragmented nature of relevant data. Public datasets on pricing trends, competitor analysis, historical wins, and losses, and countless other factors exist, but these data sets are scattered, messy, and often designed for other industries.

Vamstar begins the journey here as our expert data scientists meticulously gather these scattered datasets. We collect data on market share, penetration rates, and product adoption rates; cleaning and reshaping applying life science-specific knowledge to ensure the data brings value.

We then connect this data to produce a highly curated proprietary data set that acts as an engine for pharmaceutical intelligence.

Step 2: Harness the pattern-seeking power of AI

With the foundations laid, Vamstar’s AI-driven tools take centre stage. Using proven AI models tweaked for life science use, Vamstar builds ultra-sophisticated pattern recognition and prediction engines, trained specifically on the complexities of life science pricing.

We combine your internal data with our custom dataset to reveal hidden connections between discount levels, competitor strategies, market dynamics, and a product’s unique value proposition.

AI also monitors market changes across the lifecycle of the drug, using rigorous analysis to spot pricing opportunities. These patterns wouldn’t be visible to the naked eye, but form the basis of intelligent, profitable pricing decisions including negotiating different discounts and higher reimbursement rates.

Step 3: Automation that transforms insight into action

Data and analysis are meaningless without action, and taking the steps to price correctly is often beyond the abilities of time-pressured life sciences companies. Vamstar delivers a streamlined platform that eliminates the tedious, error-prone aspects of pricing.

Vamstar Polaris delivers data-driven pricing recommendations, scenario modelling tools, and a centralised hub for tracking pricing performance. It’s the difference between fumbling with spreadsheets and having an expert co-pilot guiding every decision.

Automation goes beyond internal efficiency. When payer negotiations begin, a supplier is already armed with hard evidence. Suppliers can confidently justify pricing not with vague promises, but with clear data demonstrating a product’s superior value.

Empowered pricing across the drug lifecycle

The impact of Vamstar’s informed, automated, AI-powered pricing platform extends far beyond a single launch or negotiation. It’s about ensuring optimal pricing at every stage of a drug’s lifecycle:
Strong foundations: Pricing is never a shot in the dark, always backed with data-driven insights that ensure initial offers are aligned with the state of the market.

• Stop costly mistakes: Prevent excel errors and miscalculations that can cost millions thanks to the safety net of set processes and extensive automation.
• Maximise pricing over the lifecycle: Vamstar ensures that manufacturers continue to drive profits even after loss of exclusivity, providing pricing data to ensure optimal price setting and price calibration through the lifecycle of the drug.
• Right offer, right customer: Compensate for shifting market conditions through AI analytics that monitor trends and buyer behaviour – and tailor offers for specific segments to prevent leakage caused by overly generalised pricing.
• Negotiation advantage: At every step, never guess what the payer might accept – work with concrete data analytics including historical trends and market and competitor intelligence.
• Profit optimisation within constraints: Find the sweet spot even within heavily regulated frameworks, by modelling different scenarios and understanding the impact of discounts.

AI-driven pricing also supports industry efforts to maximise patient outcomes by indirectly (or directly) outcomes through an improved understanding of the true value drivers for each and every stakeholder.

Dynamic pricing for a changing landscape

As profit margins remain under pressure, more market changes are on the way. It is only the suppliers that invest in getting pricing right that will manage to avoid ongoing price erosion, and squeezed profits over the lifetime of the drug.

Suppliers that harness Vamstar’s Polaris can develop a pricing strategy that’s as dynamic as the market itself, minimising missed opportunities and maximising the value a life sciences company extracts from every innovation it brings into the world.

The required data and analytics tools are out there – the time to act is now. Get in touch with Vamstar now to see how Polaris can help your organisation improve the pricing process – and your organisation’s bottom line.

AI is becoming important in medical devices, making people think about how it will affect sales and commercial teams. How can AI empower sales professionals in the medical device industry to boost customer engagement and drive revenue? This article looks at how machine learning can improve targeting prospects, customising pricing, identifying buying signals, prioritising leads, and more. It shows how this technology could change business practices significantly.

The COVID-19 pandemic has significantly influenced various facets of MedTech. On one hand, it has spurred demand for swift, accurate testing solutions and an adequate supply of personal protective equipment and medical consumables. On the other hand, it has catalysed a shift towards virtual healthcare, presenting new opportunities for medical device companies.

Yet, the postponement of non-urgent care and various economic, trade, and supply chain challenges have accelerated the digital transformation of commercial and supply chain operations in this sector. A survey encompassing 200 medical device companies revealed that 75% are undertaking some form of digital transformation initiative.

Even before the pandemic, the industry faced pressure to revamp its sales and commercial strategies. A study by BCG highlighted that MedTech companies were allocating significantly more resources to selling, general, and administrative expenses relative to their costs of goods sold than their counterparts in technology or industrial sectors.

The industry still uses outdated sales methods. These methods focus on doctors, administrators, or both. As a result, there has been no growth in sales over the last ten years.